Considering abuse liability and neurocognitive effects of cannabis and cannabis-derived products when assessing analgesic efficacy: a comprehensive review of randomized-controlled studies

References

• National Conference of State Legislatures. State Medical Marijuana Laws; 2019.
   Google Scholar
• MPP.org. Medical Marijuana Patient Numbers.
   Google Scholar
• Chart: No end in sight for Florida’s rapid medical marijuana growth. Available from: https://mjbizdaily.com/chart-no-end-florida-medical-marijuana-market-rapid-growth/ [last accessed 1 Sept 2018].
   Google Scholar
• Chart: Montana medical marijuana patient counts skyrocket in revived program. Available from: https://mjbizdaily.com/chart-montana-medical-marijuana-patient-counts-skyrocket-in-revived-program/ [last accessed 1 Sept 2018].
   Google Scholar
• Total number of registererd MMJ patients in Hawaii. Available from: https://hawaiicannabis.org/hawaii-medical-cannabis-patient-numbers-2017/ [last accessed 1 Sept 2018].
   Google Scholar
• Chart: patient numbers, medical marijuana sales spike in New Jersey. Available from: https://mjbizdaily.com/chart-patient-numbers-medical-marijuana-sales-spike-in-new-jersey/ [last accessed 1 Sept 2018].
   Google Scholar
• Bohnert KM, Perron BE, Ashrafioun L, Kleinberg F, Jannausch M, Ilgen MA. Positive posttraumatic stress disorder screens among first-time medical cannabis patients: prevalence and association with other substance use. Addict Behav. 2014;39:1414–17. doi:10.1016/j.addbeh.2014.05.022.
   PubMed Web of Science ®Google Scholar
• Bonn-Miller MO, Boden MT, Bucossi MM, Babson KA. Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users. Am J Drug Alcohol Abuse. 2014;40:23–30. doi:10.3109/00952990.2013.821477.
   PubMed Web of Science ®Google Scholar
• Cranford JA, Bohnert KM, Perron BE, Bourque C, Ilgen M. Prevalence and correlates of “Vaping” as a route of cannabis administration in medical cannabis patients. Drug Alcohol Depend. 2016;169:41–47. doi:10.1016/j.drugalcdep.2016.10.024.
   PubMed Web of Science ®Google Scholar
• National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Population Health and Public Health Practice, Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington (DC): National Academies Press (US); 2017.
   Google Scholar
• Nugent SM, Morasco BJ, O’Neil ME, Freeman M, Low A, Kondo K, Elven C, Zakher B, Motu’apuaka M, Paynter R, et al. The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review. Ann Intern Med. 2017;167:319. doi:10.7326/M17-0155.
   PubMed Web of Science ®Google Scholar
• Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313:2456.
   PubMed Web of Science ®Google Scholar
• Aviram J, Samuelly-Leichtag G. Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain Physician. 2017;20:E755–E796.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health And Human Services, Food And Drug Administration, Center For Drug Evaluation And Research (CDER). Assessment of Abuse Potential of Drugs Guidance for Industry; 2017.
   Google Scholar
• Wall MM, Liu J, Hasin DS, Blanco C, Olfson M. Use of marijuana exclusively for medical purposes. Drug Alcohol Depend. 2018. December 2018. doi:10.1016/j.drugalcdep.2018.11.009.
   Web of Science ®Google Scholar
• Ware MA, Martel MO, Jovey R, Lynch ME, Singer J. A prospective observational study of problematic oral cannabinoid use. Psychopharmacology (Berl). 2018;235:409–17. doi:10.1007/s00213-017-4811-6.
   PubMed Web of Science ®Google Scholar
• Spindle TR, Cone EJ, Schlienz NJ, Mitchell JM, Bigelow GE, Flegel R, Hayes E, Vandrey R. Acute effects of smoked and vaporized cannabis in healthy adults who infrequently use cannabis: a crossover trial. JAMA Netw Open. 2018;1:e184841. doi:10.1001/jamanetworkopen.2018.4841.
   PubMed Web of Science ®Google Scholar
• Cooper ZD, Bedi G, Ramesh D, Balter R, Comer SD, Haney M. Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability. Neuropsychopharmacology. 2018;5. doi:10.1038/s41386-018-0011-2.
   Web of Science ®Google Scholar
• Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmons S, Sansom C. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 ‘N of 1ʹ studies. Anaesthesia. 2004;59:440–52. doi:10.1111/ana.2004.59.issue-5.
   PubMed Web of Science ®Google Scholar
• Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler Houndmills Basingstoke Engl. 2004;10:434–41. doi:10.1191/1352458504ms1082oa.
   PubMed Web of Science ®Google Scholar
• Greenwald MK, Stitzer ML. Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. Drug Alcohol Depend. 2000;59:261–275. doi:10.1016/s0376-8716(99)00117-9.
   PubMed Web of Science ®Google Scholar
• Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65:812–19. doi:10.1212/01.wnl.0000176753.45410.8b.
   PubMed Web of Science ®Google Scholar
• Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain. 2007;133:210–20. doi:10.1016/j.pain.2007.03.019.
   PubMed Web of Science ®Google Scholar
• Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, Fishman S. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008;9:506–21. doi:10.1016/j.jpain.2007.12.010.
   PubMed Web of Science ®Google Scholar
• Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain. 2013;14:136–48. doi:10.1016/j.jpain.2013.06.004.
   PubMed Web of Science ®Google Scholar
• Wilsey B, Marcotte TD, Deutsch R, Zhao H, Prasad H, Phan A. An exploratory human laboratory experiment evaluating vaporized cannabis in the treatment of neuropathic pain from spinal cord injury and disease. J Pain. 2016;17:982–1000. doi:10.1016/j.jpain.2015.12.006.
   PubMed Web of Science ®Google Scholar
• Cooper ZD, Haney M. Sex-dependent effects of cannabis-induced analgesia. Drug Alcohol Depend. 2016;167:112–20. doi:10.1016/j.drugalcdep.2016.08.001.
   PubMed Web of Science ®Google Scholar
• Cooper ZD, Comer SD, Haney M. Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers. Neuropsychopharmacology. 2013;38:1984–92. doi:10.1038/npp.2013.97.
   PubMed Web of Science ®Google Scholar
• van Amerongen G, Kanhai K, Baakman AC, Heuberger J, Klaassen E, Beumer TL, Strijers RL, Killestein J, van Gerven J, Cohen A, et al. Effects on spasticity and neuropathic pain of an oral formulation of Δ9-tetrahydrocannabinol in patients withprogressive multiple sclerosis. Clin Ther. 2017. February 2017. doi:10.1016/j.clinthera.2017.01.016.
   PubMed Web of Science ®Google Scholar
• Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010;39:167–79. doi:10.1016/j.jpainsymman.2009.06.008.
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L, Weinstein S, McQuade R, Wright S, Fallon MT. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012;13:438–49.
   PubMed Web of Science ®Google Scholar
• Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil. 2003;17:21–29. doi:10.1191/0269215503cr581oa.
   PubMed Web of Science ®Google Scholar
• Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte TD, Bentley H, Gouaux B. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. Can Med Assoc J. 2012;184:1143–50.
   PubMed Web of Science ®Google Scholar
• Wallace MS, Marcotte TD, Umlauf A, Gouaux B, Atkinson JH. Efficacy of inhaled cannabis on painful diabetic neuropathy. J Pain. 2015;16:616–27. doi:10.1016/j.jpain.2015.03.008.
   PubMed Web of Science ®Google Scholar
• Wallace M, Schulteis G, Atkinson JH, Wolfson T, Lazzaretto D, Bentley H, Gouaux B, Abramson I. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology. 2007;107:785–96. doi:10.1097/01.anes.0000286986.92475.b7.
   PubMed Web of Science ®Google Scholar
• Ellis RJ, Toperoff W, Vaida F, van Den Brande G, Gonzales J, Gouaux B, Bentley H, Atkinson JH. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology. 2009;34:672–80. doi:10.1038/npp.2008.120.
   PubMed Web of Science ®Google Scholar
• Abrams DI, Vizoso HP, Shade SB, Jay C, Kelly ME, Benowitz NL. Vaporization as a smokeless cannabis delivery system: a pilot study. Clin Pharmacol Ther. 2007;82:572–78. doi:10.1038/sj.clpt.6100200.
   PubMed Web of Science ®Google Scholar
• Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain. 2004;112:299–306. doi:10.1016/j.pain.2004.09.013.
   PubMed Web of Science ®Google Scholar
• Lynch ME, Cesar-Rittenberg P, Hohmann AG. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manage. 2014;47:166–73. doi:10.1016/j.jpainsymman.2013.02.018.
   PubMed Web of Science ®Google Scholar
• Selvarajah D, Gandhi R, Emery CJ, Tesfaye S. Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care. 2010;33:128–30. doi:10.2337/dc09-1029.
   PubMed Web of Science ®Google Scholar
• Serpell M, Ratcliffe S, Hovorka J, Schofield M, Taylor L, Lauder H, Ehler E. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment: efficacy of THC/CBD spray in peripheral neuropathic pain. Eur J Pain. 2014;18:999–1012. doi:10.1002/ejp.2014.18.issue-7.
   PubMed Web of Science ®Google Scholar
• Conte A, Bettolo CM, Onesti E, Frasca V, Iacovelli E, Gilio F, Giacomelli E, Gabriele M, Aragona M, Tomassini V, et al. Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis. Eur J Pain. 2009;13:472–77. doi:10.1016/j.ejpain.2008.05.014.
   PubMed Web of Science ®Google Scholar
• Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. The Lancet. 2003;362:1517–26. doi:10.1016/S0140-6736(03)14738-1.
   PubMed Web of Science ®Google Scholar
• Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG, on behalf of the MUSEC Research Group. Multiple Sclerosis and Extract of Cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry. 2012;83:1125–1132.
   PubMed Web of Science ®Google Scholar
• Collin C, Ehler E, Waberzinek G, Alsindi Z, Davies P, Powell K, Notcutt W, O’Leary C, Ratcliffe S, Nováková I, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res. 2010;32:451–59. doi:10.1179/016164109X12590518685660.
   PubMed Web of Science ®Google Scholar
• Langford RM, Mares J, Novotna A, Vachova M, Novakova I, Notcutt W, Ratcliffe S. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol. 2013;260:984–97.
   PubMed Web of Science ®Google Scholar
• Fallon MT, Albert Lux E, McQuade R, Rossetti S, Sanchez R, Sun W, Wright S, Lichtman AH, Kornyeyeva E. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. Br J Pain. 2017;11:119–33. doi:10.1177/2049463717710042.
   PubMed Web of Science ®Google Scholar
• Lichtman AH, Lux EA, McQuade R, Rossetti S, Sanchez R, Sun W, Wright S, Kornyeyeva E, Fallon MT. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. J Pain Symptom Manage. 2018;55:179–188.e1. doi:10.1016/j.jpainsymman.2017.09.001.
   PubMed Web of Science ®Google Scholar
• Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, Gamsa A, Bennett GJ, Collet J-P. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. Can Med Assoc J. 2010;182:E694–E701. doi:10.1503/cmaj.091414.
   PubMed Web of Science ®Google Scholar
• de Vries M, van Rijckevorsel DCM, Vissers KCP, Wilder-Smith OHG, van Goor H. Tetrahydrocannabinol does not reduce pain in patients with chronic abdominal pain in a phase 2 placebo-controlled study. Clin Gastroenterol Hepatol. 2017;15:1079–1086.e4. doi:10.1016/j.cgh.2016.09.147.
   PubMed Web of Science ®Google Scholar
• Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatol Oxf Engl. 2006;45:50–52. doi:10.1093/rheumatology/kei183.
   PubMed Web of Science ®Google Scholar
• Buggy DJ, Toogood L, Maric S, Sharpe P, Lambert DG, Rowbotham DJ. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain. 2003;106:169–72. doi:10.1016/S0304-3959(03)00331-2.
   PubMed Web of Science ®Google Scholar
• Lee MC, Ploner M, Wiech K, Bingel U, Wanigasekera V, Brooks J, Menon DK, Tracey I. Amygdala activity contributes to the dissociative effect of cannabis on pain perception. Pain. 2013;154:124–34. doi:10.1016/j.pain.2012.09.017.
   PubMed Web of Science ®Google Scholar
• Kraft B, Frickey NA, Kaufmann RM, Reif M, Frey R, Gustorff B, Kress HG. Lack of Analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. Anesthesiology. 2008;109:101–10. doi:10.1097/ALN.0b013e31817881e1.
   PubMed Web of Science ®Google Scholar
• Walter C, Oertel BG, Felden L, Kell CA, Nöth U, Vermehren J, Kaiser J, Deichmann R, Lötsch J. Brain mapping-based model of Δ9-tetrahydrocannabinol effects on connectivity in the pain matrix. Neuropsychopharmacology. 2016;41:1659–69. doi:10.1038/npp.2015.336.
   PubMed Web of Science ®Google Scholar
• Conley KM, Toledano AY, Apfelbaum JL, Zacny JP. Modulating effects of a cold water stimulus on opioid effects in volunteers. Psychopharmacology (Berl). 1997;131:313–20. doi:10.1007/s002130050298.
   PubMed Web of Science ®Google Scholar
• Webb J, Kamali F. Analgesic effects of lamotrigine and phenytoin on cold-induced pain: a crossover placebo-controlled study in healthy volunteers. Pain. 1998;76:357–63. doi:10.1016/S0304-3959(98)00068-2.
   PubMed Web of Science ®Google Scholar
• Kowalczyk WJ, Evans SM, Bisaga AM, Sullivan MA, Comer SD. Sex differences and hormonal influences on response to cold pressor pain in humans. J Pain. 2006;7:151–60. doi:10.1016/j.jpain.2005.10.004.
   PubMed Web of Science ®Google Scholar
• Compton P, Kehoe P, Sinha K, Torrington MA, Ling W. Gabapentin improves cold-pressor pain responses in methadone-maintained patients. Drug Alcohol Depend. 2010;109:213–19. doi:10.1016/j.drugalcdep.2010.01.006.
   PubMed Web of Science ®Google Scholar
• Desrosiers NA, Ramaekers JG, Chauchard E, Gorelick DA, Huestis MA. Smoked cannabis’ psychomotor and neurocognitive effects in occasional and frequent smokers. J Anal Toxicol. 2015;39:251–61. doi:10.1093/jat/bkv012.
   PubMed Web of Science ®Google Scholar
• Gruber SA, Sagar KA, Dahlgren MK, Gonenc A, Smith RT, Lambros AM, Cabrera KB, Lukas SE. The grass might be greener: medical marijuana patients exhibit altered brain activity and improved executive function after 3 months of treatment. Front Pharmacol. 2018;8. doi:10.3389/fphar.2017.00983.
   PubMed Web of Science ®Google Scholar
• Ward SJ, McAllister SD, Kawamura R, Murase R, Neelakantan H, Walker EA. Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT 1A receptors without diminishing nervous system function or chemotherapy efficacy: cannabidiol prevents chemotherapy neuropathic pain. Br J Pharmacol. 2014;171:636–45. doi:10.1111/bph.12439.
   PubMed Web of Science ®Google Scholar
• Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl). 1982;76:245–50. doi:10.1007/BF00432554.
   PubMed Web of Science ®Google Scholar
• Nicholson AN, Turner C, Stone BM, Robson PJ. Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacol. 2004;24:305–13. doi:10.1097/01.jcp.0000125688.05091.8f.
   PubMed Web of Science ®Google Scholar
• Morgan CJA, Schafer G, Freeman TP, Curran HV. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. Br J Psychiatry. 2010;197:285–90. doi:10.1192/bjp.bp.110.077503.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya S. Induction of psychosis byΔ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch Gen Psychiatry. 2012;69:27. doi:10.1001/archgenpsychiatry.2012.513.
   PubMed Web of Science ®Google Scholar
• Morgan CJA, Gardener C, Schafer G, Swan S, Demarchi C, Freeman TP, Warrington P, Rupasinghe I, Ramoutar A, Tan N, et al. Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychol Med. 2012;42:391–400. doi:10.1017/S0033291711001322.
   PubMed Web of Science ®Google Scholar
• Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, Stone JM, Reichenberg A, Brenneisen R, Holt D, et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol (Oxf). 2013;27:19–27. doi:10.1177/0269881112460109.
   PubMed Web of Science ®Google Scholar
• Smart R, Caulkins JP, Kilmer B, Davenport S, Midgette G. Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state: legal cannabis potency and price variation. Addiction. 2017;112:2167–77. doi:10.1111/add.13886.
   PubMed Web of Science ®Google Scholar
• Rog DJ, Nurmikko TJ, Young CA. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther. 2007;29:2068–79. doi:10.1016/j.clinthera.2007.09.013.
   PubMed Web of Science ®Google Scholar
• Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler Houndmills Basingstoke Engl. 2006;12:639–45. doi:10.1177/1352458505070618.
   PubMed Web of Science ®Google Scholar
• Comer SD, Sullivan MA, Whittington RA, Vosburg SK, Kowalczyk WJ. Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. Neuropsychopharmacology. 2008;33:1179–91. doi:10.1038/npp.2008.45.
   PubMed Web of Science ®Google Scholar
• Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs. 2017;77:403–26. doi:10.1007/s40265-017-0731-3.
   PubMed Web of Science ®Google Scholar
• Mintzer MZ, Lanier RK, Lofwall MR, Bigelow GE, Strain EC. Effects of repeated tramadol and morphine administration on psychomotor and cognitive performance in opioid-dependent volunteers. Drug Alcohol Depend. 2010;111:265–68. doi:10.1016/j.drugalcdep.2010.05.002.
   PubMed Web of Science ®Google Scholar
• Salinsky MC, Binder LM, Oken BS, Storzbach D, Aron CR, Dodrill CB. Effects of gabapentin and carbamazepine on the EEG and cognition in healthy volunteers. Epilepsia. 2002;43:482–90. doi:10.1046/j.1528-1157.2002.22501.x.
   PubMed Web of Science ®Google Scholar
• Schoedel KA, Chen N, Hilliard A, White L, Stott C, Russo E, Wright S, Guy G, Romach MK, Sellers EM. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use: a study of the abuse potential of nabiximols. Hum Psychopharmacol Clin Exp.2011; n/a-n/a.
   PubMed Web of Science ®Google Scholar
• Arkell TR, Lintzeris N, Kevin RC, Ramaekers JG, Vandrey R, Irwin C, Haber PS, McGregor IS. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Psychopharmacology (Berl). 2019;1. doi:10.1007/s00213-019-05246-8.
   Web of Science ®Google Scholar
• Perron BE, Holt KR, Yeagley E, Ilgen M. Mental health functioning and severity of cannabis withdrawal among medical cannabis users with chronic pain. Drug Alcohol Depend. 2019;194:401–09. doi:10.1016/j.drugalcdep.2018.09.029.
   PubMed Web of Science ®Google Scholar
• Serpell MG, Notcutt W, Collin C. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. J Neurol. 2013;260:285–95. doi:10.1007/s00415-012-6683-3.
   PubMed Web of Science ®Google Scholar
• Notcutt W, Langford R, Davies P, Ratcliffe S, Potts R. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols). Mult Scler J. 2012;18:219–28. doi:10.1177/1352458511419700.
   PubMed Web of Science ®Google Scholar